Company Description
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally.
It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.
The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories.
It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors.
IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
| Country | United States |
| Founded | 1992 |
| IPO Date | Jul 16, 2014 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 148 |
| CEO | Roger Susi |
Contact Details
Address: 1025 Willa Springs Drive Winter Springs, Florida 32708 United States | |
| Phone | 407 677 8022 |
| Website | iradimed.com |
Stock Details
| Ticker Symbol | IRMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001325618 |
| CUSIP Number | 46266A109 |
| ISIN Number | US46266A1097 |
| Employer ID | 73-1408526 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Roger E. Susi | Founder, Chairman, Chief Executive Officer and President |
| John F. Glenn | Chief Financial Officer and Corporate Secretary |
| Randy Waddell | Vice President of Worldwide Sales and Marketing |
| Chris Williamson | Executive Vice President of Continuous Improvement and Information Technology |
| Matt Garner | Controller |
| Steve Kachelmeyer | Vice President of Regulatory Affairs and Quality Assurance |
| Lynn Neuhardt | Vice President of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 1, 2024 | 10-Q | Quarterly Report |
| Aug 1, 2024 | 8-K | Current Report |
| Jun 20, 2024 | 8-K | Current Report |
| Jun 7, 2024 | 8-K | Current Report |
| Jun 3, 2024 | 144 | Filing |
| Jun 3, 2024 | 8-K | Current Report |
| May 9, 2024 | ARS | Filing |
| May 8, 2024 | EFFECT | Notice of Effectiveness |
| May 6, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |